A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

PURPOSE: This phase I study was conducted to identify the MTD of alvocidib when combined vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2 (RAEB-2). Secondary objectives included investigating the pharmacokinetic and pharmac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Holkova, Beata, Supko, Jeffrey G., Ames, Matthew M., Reid, Joel M., Shapiro, Geoffrey I., Tombes, Mary Beth, Honeycutt, Connie, McGovern, Renee M., Kmieciak, Maciej, Shrader, Ellen, Wellons, Martha D., Sankala, Heidi, Roberts, John D., Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618599/
https://ncbi.nlm.nih.gov/pubmed/23515411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2926
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados